Inhibitory effects of tricin derivative from Sasa albo-marginata on replication of human cytomegalovirus

Antiviral Research

Volumn 91, Issue 3, 2011, Pages 296-303

  Akuzawa, Kazuhiko ^a   Yamada, Rie ^a   Li, Zhuan ^a   Li, Ying ^a   Sadanari, Hidetaka ^a   Matsubara, Keiko ^a   Watanabe, Kunitomo ^b   Koketsu, Mamoru ^b   Tuchida, Yuuzo ^c   Murayama, Tsugiya ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Hououdou Co Ltd   (Japan)

Author keywords

Anti cytomegalovirus activity; COX 2; Entry; HCMV; IE2; Tricin

Indexed keywords

40',5,7 TRIHYDROXY 30,50 DIMETHOXYFLAVONE; ANTIVIRUS AGENT; CYCLOOXYGENASE 2; DNA POLYMERASE; FLAVONE DERIVATIVE; GANCICLOVIR; MESSENGER RNA; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EMBRYO; FETUS; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SASA; VIRUS CULTURE; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; CYCLOOXYGENASE 2; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DINOPROSTONE; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; FIBROBLASTS; FLAVONOIDS; GANCICLOVIR; HUMANS; IMMEDIATE-EARLY PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SASA; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; SASA;

EID: 79960677182     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.06.014     Document Type: Article

References (47)

1. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 71:154-163.
2. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46:2365-2372.
3. Buerger I., Reefschlaeger J., Bender W., Eckenberg P., Popp A., Weber O., Graeper S., Klenk H.D., Ruebsamen-Waigmann H., Hallenberger S. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 2001, 75:9077-9086.
4. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15(532-534):536-537.
5. Compton T., Nepomuceno R.R., Nowlin D.M. Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 1992, 191:387-395.
6. Compton T., Nowlin D.M., Cooper N.R. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 1993, 193:834-841.
7. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., Rozenheim M., Baumelou A., Dohin E., Gentilini M., Jacobs C. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. 1989, 9:316-321.
8. Freitas V.R., Fraser-Smith E.B., Matthews T.R. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989, 12:205-212.
9. Furukawa T., Fioretti A., Plotkin S. Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication. J. Virol. 1973, 11:991-997.
10. Gebhardt B.M., Varnell E.D., Kaufman H.E. Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation. J. Ocul. Pharmacol. Ther. 2005, 21:114-120.
11. Gönczöl E., Andrews P.W., Plotkin S.A. Cytomegalovirus replicates in differentiated but not in undifferentiated human embryonal carcinoma cells. Science 1984, 224:159-161.
12. Ho M. Virus infections after transplantation in man. Brief review. Arch. Virol. 1977, 55:1-24.
13. Ho E.S., Lin D.C., Mendel D.B., Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 2000, 11:383-393.
14. Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J. Virol. 2009, 83:12388-12398.
15. Jacobs J.P., Jones C.M., Baille J.P. Characteristics of a human diploid cell designated MRC-5. Nature 1970, 227:168-170.
16. Jassim S.A., Naji M.A. Novel antiviral agents: a medicinal plant perspective. J. Appl. Microbiol. 2003, 95:412-427.
17. Kuboyama N., Fujii A., Tamura T. Antitumor activities of bamboo leaf extracts (BLE) and its lignin (BLL). Nippon Yakurigaku Zasshi 1981, 77:579-596.
18. Lischka P., Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 2008, 8:541-548.
19. Lischka P., Hewlett G., Wunberg T., Baumeister J., Paulsen D., Goldner T., Ruebsamen-Schaeff H., Zimmermann H. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 2010, 54:1290-1297.
20. Marchini A., Liu H., Zhu H. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 2001, 75:1870-1878.
21. Maussang D., Langemeijer E., Fitzsimons C.P., Stigter-van Walsum M., Dijkman R., Borg M.K., Slinger E., Schreiber A., Michel D., Tensen C.P., van Dongen G.A., Leurs R., Smit M.J. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res. 2009, 69:2861-2869.
22. McSharry J.J., McDonough A., Olson B., Talarico C., Davis M., Biron K.K. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole l-riboside 1263W94. Clin. Diagn. Lab. Immunol. 2001, 8:1279-1281.
23. Mocarski E., Shenk T., Pass R. Cytomegaloviruses 2007, Lippincott Williams & Wilkins, Philadelphia, PA.
24. Murayama T., Jisaki F., Ayata M., Sakamuro D., Hironaka T., Hirai K., Tsuchiya N., Ito K., Furukawa T. Cytomegalovirus genomes demonstrated by polymerase chain reaction in synovial fluid from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1992, 10:161-164.
25. Murayama T., Mukaida N., Khabar K.S., Matsushima K. Potential involvement of IL-8 in the pathogenesis of human cytomegalovirus infection. J. Leukoc. Biol. 1998, 64:62-67.
26. Murayama T., Mukaida N., Sadanari H., Yamaguchi N., Khabar K.S., Tanaka J., Matsushima K., Mori S., Eizuru Y. The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression. Biochem. Biophys. Res. Commun. 2000, 279:298-304.
27. Nishiwaki M., Fujimuro M., Teishikata Y., Inoue H., Sasajima H., Nakaso K., Nakashima K., Sadanari H., Yamamoto T., Fujiwara Y., Ogawa N., Yokosawa H. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay. J. Med. Virol. 2006, 78:1635-1642.
28. Noble S., Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998, 56:115-146.
29. Patrone M., Secchi M., Bonaparte E., Milanesi G., Gallina A. Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J. Virol. 2007, 81:11479-11488.
30. Petrik D.T., Schmitt K.P., Stinski M.F. Inhibition of cellular DNA synthesis by the human cytomegalovirus IE86 protein is necessary for efficient virus replication. J. Virol. 2006, 80:3872-3883.
31. Sakai A., Watanabe K., Koketsu M., Akuzawa K., Yamada R., Li Z., Sadanari H., Matsubara K., Muroyama T. Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata (Kumazasa in Japan). Antivir. Chem. Chemother. 2008, 19:125-132.
32. Scholz M., Doerr H.W., Cinatl J. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option?. Antiviral Res. 2001, 49:129-145.
33. Schröer J., Shenk T. Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 2008, 105:19468-19473.
34. Shibata M., Yamatake Y., Sakamoto M., Kanamori M., Takagi K. Phamacological studies on bamboo grass (1). Acute toxicity and anti-inflammatory and antiulcerogenic activities of water-soluble fraction (Folin) extracted from Sasa albomarginata Makino et Shibata. Nippon Yakurigaku Zasshi 1975, 71:481-490.
35. Shibata M., Kubo K., Onoda M. Pharmacological studies on bamboo grass. (2) Central depressant and antitoxic actions of a water-soluble fraction (folin) extracted from Sasa albomarginata Makino et Shibata. Nippon Yakurigaku Zasshi 1976, 72:531-541.
36. Sissons J.G., Carmichael A.J. Clinical aspects and management of cytomegalovirus infection. J. Infect. 2002, 44:78-83.
37. Speir E., Yu Z.X., Ferrans V.J., Huang E.S., Epstein S.E. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ. Res. 1998, 83:210-216.
38. Taylor R.T., Bresnahan W.A. Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression. J. Virol. 2006, 80:920-928.
39. Taylor H.P., Cooper N.R. The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein. J. Virol. 1990, 64:2484-2490.
40. Wachsman M., Aurelian L., Burnett J.W. The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections. Br. J. Dermatol. 1990, 123:375-380.
41. Wentworth B.B., French L. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 1970, 135:253-258.
42. Yi H.A., Kim M.S., Jang S.Y., Lee Y.M., Ahn J.H., Lee C.H. Cellular signals involved in cyclooxygenase-2 expression induced by human cytomegalovirus. Virus Res. 2009, 146:89-96.
43. Yukawa T.A., Kurokawa M., Sato H., Yoshida Y., Kageyama S., Hasegawa T., Namba T., Imakita M., Hozumi T., Shiraki K. Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antiviral Res. 1996, 32:63-70.
44. Zaia J.A. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin. Infect. Dis. 1993, 17(Suppl. 2):S392-399.
45. Zhen H., Fang F., Ye D.Y., Shu S.N., Zhou Y.F., Dong Y.S., Nie X.C., Li G. Experimental study on the action of allitridin against human cytomegalovirus in vitro: Inhibitory effects on immediate-early genes. Antiviral Res. 2006, 72:68-74.
46. Zhou H., Ivanov V.N., Gillespie J., Geard C.R., Amundson S.A., Brenner D.J., Yu Z., Lieberman H.B., Hei T.K. Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway. Proc. Natl. Acad. Sci. USA 2005, 102:14641-14646.
47. Zhu H., Cong J.P., Yu D., Bresnahan W.A., Shenk T.E. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl. Acad. Sci. USA 2002, 99:3932-3937.